Claims
- 1. A monoclonal antibody that specifically recognizes a stimulant or hallucinogenic drug of abuse or a metabolite thereof, wherein said drug of abuse or its metabolite is selected from the group consisting of d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, (+) 3,4-methylenedioxyamphetamine and structural-related analogs of these compounds.
- 2. The monoclonal antibody of claim 1, wherein said antibody is of murine origin.
- 3. The monoclonal antibody of claim 1, wherein said antibody is of human origin or contains portions of a human antibody
- 4. An antigen binding fragment that specifically recognizes a stimulant or hallucinogenic drug of abuse or a metabolite thereof, wherein said drug of abuse or its metabolite is selected from the group consisting of d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, (+) 3,4-methylenedioxyamphetamine and structural-related analogs of these compounds.
- 5. The antigen binding fragment of claim 4, wherein said antigen binding fragment is of murine origin.
- 6. The antigen binding fragment of claim 4, wherein said antigen binding fragment is of human origin or contains portions of a human antibody.
- 7. A method of treating stimulant or hallucinogenic drug abuse and/or overdose, comprising the step of administering a pharmacological effective dose of the monoclonal antibody of claim 1 to an individual in need of such treatment.
- 8. The method of claim 7, wherein said stimulant or hallucinogenic drug is d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, (+/−) 3,4-methylenedioxyamphetamine and structural-related analogs of these compounds.
- 9. A method of treating stimulant drug abuse and/or overdose, comprising the step of administering a pharmacological effective dose of the antigen binding fragment of claim 4 to an individual in need of such treatment.
- 10. The method of claim 9, wherein said stimulant or hallucinogenic drug is d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, (+/−) 3,4-methylenedioxyamphetamine and structural-related analogs of these compounds.
- 11. A compound with the structure of
- 12. A method of generating a class-specific monoclonal antibody that recognizes methamphetamine-like stimulants, comprising the step of:
immunizing animals with the compound of claim 11; generating antibody-secreting hybridomas from the spleen cells of said animals; and screening the specificity of the antibodies, wherein antibody showing cross-reactivity to methamphetamine-like stimulants indicates the generation of methamphetamine-like stimulants-specific antibody.
- 13. A compound with the structure of
- 14. The compound of claim 13, wherein R is O(CH2)XCOOH, and X is from 2 to 9.
- 15. The compound of claim 13, wherein R is OCH2CH═CH(CH2)XCOOH, and X is from 1 to 6.
- 16. The compound of claim 13, wherein R is OCH2C═C(CH2)XCOOH, and X is from 1 to 6.
- 17. The compound of claim 13, wherein R is O(CH2)XO(CH2)YCOOH, and X is from 2 to 4, Y is from 1 to 5.
- 18. The compound of claim 13, wherein R is O(CH2)XNR1(CH2)YCOOH, X is from 2 to 3, Y is from 1 to 5, and R1 is alkyl 1-5 carbon.
- 19. The compound of claim 13, wherein R is S(CH2)XCOOH, and X is from 2 to 9.
- 20. The compound of claim 13, wherein R is SCH2CH═CH(CH2)XCOOH, and X is from 1 to 6.
- 21. The compound of claim 13, wherein R is SCH2C═C(CH2)XCOOH, and X is from 1 to 6.
- 22. The compound of claim 13, wherein R is S(CH2)XO(CH2)YCOOH, and X is from 2 to 4, Y is from 1 to 5.
- 23. The compound of claim 13, wherein R is S(CH2)XNR1(CH2)YCOOH, X is from 2 to 3, Y is from 1 to 5, and R1 is alkyl 1-5 carbon.
- 24. The compound of claim 13, wherein R is (CH2)XCOOH, and X is from 3 to 8.
- 25. The compound of claim 13, wherein R is (CH2)XCH═CHCOOH, and X is from 2 to 7.
- 26. The compound of claim 13, wherein R is (CH2)XC═CCOOH, and X is from 2 to 7.
- 27. The compound of claim 13, wherein R is CH═CH(CH2)XCOOH, and X is from 1 to 6.
- 28. The compound of claim 13, wherein R is C═C(CH2)XCOOH, and X is from 1 to 6.
- 29. The compound of claim 13, further comprises of a hydrocarbon structure R1 attached to R, wherein R1 is selected from the group consisting of —CH2CH2CN,
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This non-provisional patent application claims benefit of provisional patent application U.S. Ser. No. 60/198,902, filed Apr. 20, 2000, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60198902 |
Apr 2000 |
US |